Prellis Biologics’ Post

🚀 𝗨𝗽𝗰𝗼𝗺𝗶𝗻𝗴 #FREE 𝗪𝗲𝗯𝗶𝗻𝗮𝗿: 𝗔𝗜-𝗯𝗮𝘀𝗲𝗱 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗔𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝗜𝘁𝘀 𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗶𝗻𝗴 Join us tomorrow to explore how AI-based platforms are transforming the development of antibody therapeutics, ensuring they are effective and viable for large-scale production and clinical use. 👉Register here: https://ow.ly/9fS050RTIn2 What you will learn from the webinar 🔹Importance and challenges of developability in antibody therapeutics 🔹Role of AI in transforming developability assessment 🔹Technological solutions for antibody developability assessment and engineering #AntibodyTherapeutics #Biotech #Webinar #AntibodyDevelopment #MonoclonalAntibodies #mAb #PTM #AntibodyEngineering #AI

In this new post (4-min read), John S. Kenney, Ph.D. (Antibody Solutions) offers a brief recap of content presented at Antibody Engineering & Therapeutics 2023, sharing his thoughts on Will AI Kill the Lab?, Accessing New Technologies, and New Horizons. Thanks, John! #antibodyengineering #ai #antibodies #antibodytherapeutics https://lnkd.in/d_gUGYcN

What role does AI play in drug discovery? 🔍 AI can predict the efficacy and toxicity of potential drug compounds more quickly and at a lower cost. 💲 As 85% of targets are deemed ‘undruggable’, AI could help increase the druggability of various diseases, by better understanding the structure of these targets. 🔬 This week, we are in conversation with Kyle Tretina, PhD, alliance manager of AI Platforms at Insilico Medicine to discuss drug discovery, undruggable targets, and an exciting, new collaboration that aims to test AI-designed molecules against undruggable cancer targets. 🎯 🎧 Tune in to the latest episode of the Beyond Biotech Podcast to find out more! 👇 https://lnkd.in/dVjewifZ #BeyondBiotechPodcast #AI #drugdiscovery #pharma #bioinformatics #medtech #healthtech #drugdevelopment #research #innovation #undruggabletargets #drugefficacy #medicalresearch University of Toronto

🚀 𝗨𝗽𝗰𝗼𝗺𝗶𝗻𝗴 𝗪𝗲𝗯𝗶𝗻𝗮𝗿: 𝗔𝗜-𝗯𝗮𝘀𝗲𝗱 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗔𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝗜𝘁𝘀 𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗶𝗻𝗴 Join us to explore how AI-based platforms are transforming the development of antibody therapeutics, ensuring they are effective and viable for large-scale production and clinical use. 👉Register here: https://ow.ly/9fS050RTIn2 What you will learn from the webinar 🔹Importance and challenges of developability in antibody therapeutics 🔹Role of AI in transforming developability assessment 🔹Technological solutions for antibody developability assessment and engineering #AntibodyTherapeutics #Biotech #Webinar #AntibodyDevelopment #MonoclonalAntibodies #mAb #PTM #AntibodyEngineering #AI

Exciting news! CatSci Ltd and REACH INDUSTRIES have secured an Innovate UK grant to accelerate the development of life-changing oligonucleotide therapeutics. This grant will fund a collaboration that combines scientific expertise with machine vision tools to streamline the synthesis, purification and analysis of RNA medicines. Dr Sam Whitmarsh, our Director of Analytical Science and Digital Transformation, commented: “I’m thrilled that we have won the Innovate UK grant. The partnership between CatSci and Reach Industries will leverage AI and machine learning tools to accelerate the development of oligonucleotide therapies. Together, we will use the funding from Innovate UK to build standardised workflows that will allow our customers to advance their RNA therapeutics seamlessly through development. Both CatSci and Reach Industries are driven by a common purpose: powering scientific expertise with cutting edge digital tools to help patients in need.” Read the press release here: https://lnkd.in/esd9pDrw #ExcellenceInMedicinesDevelopment #ProudToBeCatSci #oligonucleotides #RNAtherapeutics #transformingmedicinesmanufacturing #AI #MachineLearning #ML

Join ABclonal Technology's upcoming webinar with Dr. Hao Derek Cheng and Dr. Kin Leung, Ph.D. while they dive into #antibody engineering! They'll be chatting about the following topics: ▪️Tailored antibody formats, including antibody fragments and nanobodies ▪️Improving deliverability ▪️Reducing immunogenicity through antibody humanization ▪️Enhancing stability and solubility ▪️Creating bi- and multi-specific antibodies, antibody-drug conjugates, and more If you don't want to miss out, you can register below and add it to your calendar 🙂

Emerging Trends in Life Sciences: A 2024 Outlook Exciting times are ahead for the commercial life sciences sector, especially within the pharmaceutical and biotech industries! As we navigate through 2024, a couple of groundbreaking shifts are setting the stage for innovation and growth. Here's what's catching the eye: Biotech Boom 🌟: The biotech sector is buzzing with optimism, driven by a surge in IPOs and acquisitions. A recent survey by ICON Biotech revealed that 60% of decision-makers anticipate increased R&D spending over the next two years. This financial injection is expected to fuel advancements in Alzheimer's treatment, obesity, AI applications, and cutting-edge cell and gene therapies. Dive deeper into the biotech landscape https://lnkd.in/eNJ7FrcC (Fierce Biotech). Pharma Innovations 💊: The pharmaceutical industry is embracing technology like never before, with a strong focus on improving clinical trials, expanding patient diversity, and strengthening drug safety systems. The integration of real-world data and generative AI is proving to be a game-changer, enabling personalized therapies and enhancing trial designs. For an in-depth look at these shifts, check out the full article https://lnkd.in/edZJnZf3). Regulatory Reinvention 📜: Regulatory trends are undergoing a significant transformation, propelled by AI and global harmonization. Predictions indicate that AI will manage a majority of pre-market compliance tasks by 2025, leading to more efficient regulatory processes. Additionally, a move towards digital dossiers and global regulatory frameworks promises to streamline compliance and approval processes. Learn more about these regulatory trends https://lnkd.in/eN3G_4gv (Freyr). These developments signal a vibrant future for the life sciences industry, promising enhanced efficiency, innovation, and patient outcomes. Stay tuned and engaged with these trends to leverage the opportunities they present. 🔗💼 #BiotechInnovation #PharmaTrends2024 #RegulatoryTransformation #LifeSciences2024 #FutureOfHealthcare

🚀 Biotech Trends 2024: Paving the Future of Healthcare Exciting times ahead for the biotech industry! Here are the key trends shaping 2024: Gene Editing & CRISPR: Revolutionizing drug development by targeting genetic anomalies. Think precision in treating diseases like cystic fibrosis and sickle cell anemia. Stem Cell Technology: Redefining drug development with personalized medicine and potential applications in regenerative medicine for conditions like heart disease and Parkinson's. AI & Machine Learning: Accelerating drug discovery, designing novel drug molecules, and personalizing medicine for more effective treatments. Tissue Engineering & Bioprinting: Innovating drug development with 3D tissue models, personalized drug screening, and customized drug delivery systems. Real World Evidence Trials: Transforming drug development strategies by leveraging real-world data for personalized treatments and efficient validation. Collaboration with CROs: Biotech companies teaming up with Contract Research Organizations for specialized expertise, cutting-edge resources, and streamlined processes. Bio-to-Bio Outsourcing: Synergistic partnerships among biotech companies, accelerating development timelines and fostering collaborative innovation. Investment Patterns & M&A: A focus on mergers and acquisitions in gene editing and AI-driven discovery, with potential growth opportunities in new technologies like mRNA vaccines. Exciting times for the biotech landscape! 🌐💡#biotech #biotechnology #pharma #pharmaceuticalindustry Source: https://lnkd.in/gxEc6EMc

Available in the BNLX via BIOKÉ ! Please contact us for an onsite demo at the ErasmusMC Rotterdam Traditionally, DNA cloning has been a cornerstone in the development of new therapies, but it's a time-consuming and complex process. Now, imagine bypassing this step entirely—saving time, resources, and accelerating your path to discovery. That's exactly what BioXP-synthesized mRNA technology enables us to do. By using synthesized mRNA directly, we can screen potential therapeutic candidates up to 3 times faster than traditional methods. This isn't just about speed, but also about increasing the efficiency and precision of our screening processes. Embracing BioXP-synthesized mRNA means more efficient, precise screening, transforming how we develop therapies for antibody discovery and immunotherapy. Find out more --->https://lnkd.in/gBPySnti

Secure your COMPLIMENTARY pass to the AI in Drug Discovery Xchange - Brussels 2024! 🚨 Grab your pass here: https://lnkd.in/eaupZYTB 🗓️ Mark your calendars for 21st November 2024 at 09:05 - 10:05 for an exclusive roundtable discussion on "Applying omic data analytics for personalized drug response prediction." 🔬🧬 Key topics include: • Emerging alternatives to DNA (WGS, NGS), RNA expression, or DNA methylation omic data. Is proteomics 🧫 or single-cell RNA seq 🔍 the next big thing? • Limitations of foundational AI models for drug response prediction 🤖. • Pros and cons of multi-omic 🧬 approaches in drug response prediction. • Challenges in transferring biomarker detection models 🧪 to clinical trials, especially in oncology 🧑🔬. • Cohort selection strategies 📊 and maximizing response rates. 💡 Industry Expert: Marcin Kowiel, Associate Director - Data Science & AI Platforms at Ryvu Therapeutics, will lead the discussion. With a strong background in AI, machine learning, and biomarker discovery 🧠, Marcin brings valuable insights from his experience in oncology drug development. 🔗 Register today and secure your spot in this forward-looking session! Don’t miss the chance to dive into the latest trends and challenges in omic data analytics and personalized medicine 💻. Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #AIinDrugDiscovery #OmicData #PersonalizedMedicine #DrugResponsePrediction #ClinicalTrials #Biomarkers #Oncology #Proteomics #SingleCellRNAseq #MultiOmics #DataScience #AIandML #Bioinformatics #TranslationalResearch #PrecisionMedicine #BigDataInHealthcare #CancerResearch #BiotechInnovation #AIinHealthcare #PharmaR&D #LeadOptimization #TargetDiscovery #NextGenSequencing #BioTech #HealthTech #Xchange2024 #PharmaTech #Biopharma #Brussels2024 #ScientificRoundtable #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass